BRIEF—Farxiga reduced hospitalization for heart failure regardless of ejection fraction status

Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that AstraZeneca’s Farxiga (dapagliflozin) reduced the relative risk of major adverse cardiovascular events (MACE) by 16% compared to placebo in patients with type-2 diabetes (T2D) who had a prior heart attack (myocardial infarction).

In another pre-specified sub-analysis, Farxiga compared to placebo reduced the relative risk of hospitalisation for heart failure (hHF) in patients with T2D regardless of their ejection fraction (EF) status, a measurement of the percentage of blood leaving the heart with each contraction.

The data were presented today at the American College of Cardiology’s (ACC) 68th Annual Scientific Session, New Orleans, USA and were published in Circulation.

These pre-specified sub-analyses of DECLARE-TIMI 58 add to the positive primary results of the trial presented in November 2018, which showed that Farxiga significantly reduced the risk of the composite of hHF or CV death compared to placebo, consistently across the trial’s entire patient population.

Additionally, there were fewer major adverse cardiovascular events observed with Farxiga in the broad patient population, however this did not reach statistical significance.